We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
279 49 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
279Another approach to CD47. nature.comsemi_infinite -July 3
278Wow. I wonder what it could do in earlier interventions, or even if that is waratticus4paws-June 13
277AFMD - AFM13 combo with Pembro continues to impress. onlinelibrary.wiley.comsemi_infinite -June 13
276Tweet regarding Forty-Seven's updated results (which aren't being receivtuck-May 16
275"It will some time and some more dilution before they have much to show anysemi_infinite -April 30
274So Dr. Stiernholm is out, and Dr. Uger takes the helm for the moment. Share prituck-April 30
273Arch gets funding for ph 1 trial. businesswire.comsemi_infinite -March 26
272>>Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPa axis and tuck-March 5
271Good idea to see if all time low at 0.48 holds. IMO it gets tested at the leastsemi_infinite -March 1
270No rush on my side. Too many mistakes.Miljenko Zuanic-February 28
26920+ abstracts at AACR when cd47 used in search. Interesting one from Arch Onco semi_infinite -February 28
268Well, one take-home from the publication that Tuck just pointed to is that CD47 scaram(o)uche-February 22
267Wasn't aware that it is. Haven't submitted a contest entry with any effscaram(o)uche1February 22
266622 is there chance that this may work in combo...60c/share is not Miljenko Zuanic-February 22
265Rick, Why is TRIL in your Contest portfolio? You seem to had this right all alBladerunner17-February 22
264>> what do you think of scaramouche's criticisms of TRIL? << Clscaram(o)uche-February 22
263One quarter of operating expenses is a band aid unless some spectacular data comsemi_infinite -February 22
262And one warrant per unit at 96 cents. Jeez. Cheers, Tucktuck-February 22
261Say, it's been a while since I've been asked by the IR team to update thtuck1February 22
260Today's stories, two biotechs (immunotherapy of cancer) that ran out of monescaram(o)uche-February 21
259The modestly increased volume and capped price caught my eye today. The ask wasscaram(o)uche-February 21
258The first two authors contributed equally to the work. Second author is from Irscaram(o)uche-February 21
257A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRPtuck-February 21
256Am seeing an offering of $15 million @ 80 cents/share. Wondering if I dare taketuck-February 21
255CD16A subset (158F, 85% of patients) is a thing of beauty. Read-through to AFMDscaram(o)uche-February 6
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):